ClinicalTrials.gg

Program

imeglimin

Also written as “Imeglimin” and “Imeglimin Hydrochloride Film Coated Tablet”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.

Furthest: phase 2, since Sep 19, 20137 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Poxel60 open or runningphase 2since Sep 19, 2013Sep 19, 2013none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Jul 1, 2026Jul 1, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2013First study: phase 2 study in Diabetes Mellitus, Type 2New to PoxelPoxel · NCT01951235 · 315 enrolled · Latvia
  2. Feb 2, 2015Phase 1 study in Diabetes Mellitus, Type 2Poxel · NCT02373150 · 48 enrolled · United Kingdom
  3. Oct 4, 2016Phase 1 study in Qt Interval, Variation inPoxel · NCT02924337 · 55 enrolled · United Kingdom
  4. Jun 8, 2018Phase 1 study in HealthyPoxel · NCT03618316 · 16 enrolled · United Kingdom
  5. Aug 23, 2018Phase 1 study in BioequivalencePoxel · NCT03646331 · 16 enrolled · United Kingdom
  6. Jan 10, 2019Phase 1 study in Hepatic ImpairmentPoxel · NCT03802786 · 14 enrolled · Germany
  7. Jul 1, 2026Humanis Saglık Anonim Sirketi's first study: phase 1 study in Diabetes Mellitus, Type 2New to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07691177 · 40 enrolled · India

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07691177Diabetes Mellitus, Type 2 · India1CompletedHumanis Saglık Anonim SirketiMar 27, 202640
NCT03802786Hepatic Impairment · Germany1CompletedPoxelJul 3, 201914
NCT03646331Bioequivalence · United Kingdom1CompletedPoxelSep 27, 201816
NCT03618316Healthy · United Kingdom1CompletedPoxelJul 21, 201816
NCT02924337Qt Interval, Variation in · United Kingdom1CompletedPoxelDec 201655
NCT02373150Diabetes Mellitus, Type 2 · United Kingdom1CompletedPoxelOct 201548
NCT01951235Diabetes Mellitus, Type 2 · Latvia2CompletedPoxelJul 2014315

How it is read

Names in the registry

  • “Imeglimin”, 6 entries
  • “Imeglimin Hydrochloride Film Coated Tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
imeglimin (Poxel): development program | ClinicalTrials.gg